IndustryPayments
Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

HOWARD TRACHTMAN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Nephrology

NPI
1942360011
CMS profile
360429
Location
NEW YORK, NY

General Payments · PY2020–2024

$190,498.27

  • Reported across 111 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$108,689.11

47 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

Related groups: Pediatric Nephrology NY All categories

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $100,760.00 40
Travel and Lodging $7,789.06 3
Food and Beverage $140.05 4

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim International GmbH $44,009.11 17
Boehringer Ingelheim Pharmaceuticals, Inc. $34,625.00 12
Retrophin, Inc. $22,375.00 13
Alexion Pharmaceuticals, Inc. $3,350.00 2
Otsuka Pharmaceutical Development & Commercialization, Inc. $2,860.00 2
AstraZeneca UK Limited $1,470.00 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,041.85 2
PY2021 $5,556.99 7
PY2022 $14,596.19 20
PY2023 $59,614.13 35
PY2024 $108,689.11 47

Payment records · PY2024 (47)

Sorted by paying entity, then date · as published by CMS

Program year 2024 2020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Alexion Pharmaceuticals, Inc. $2,680.00 04/02/2024 Consulting Fee Undisputed 01/23/2026 1094042052 CMS
Alexion Pharmaceuticals, Inc. $670.00 10/31/2024 Consulting Fee Undisputed 01/23/2026 1093916115 CMS
AstraZeneca UK Limited $1,470.00 11/25/2024 Consulting Fee Undisputed 01/23/2026 1093948370 CMS
Boehringer Ingelheim International GmbH $1,625.00 01/10/2024 Consulting Fee Undisputed 01/23/2026 1118244314 CMS
Boehringer Ingelheim International GmbH $2,600.00 04/12/2024 Consulting Fee Undisputed 01/23/2026 1118244326 CMS
Boehringer Ingelheim International GmbH $3,575.00 06/13/2024 Consulting Fee Undisputed 01/23/2026 1118244336 CMS
Boehringer Ingelheim International GmbH $3,250.00 06/25/2024 Consulting Fee Undisputed 01/23/2026 1118244332 CMS
Boehringer Ingelheim International GmbH $4,255.00 06/25/2024 Consulting Fee Undisputed 01/23/2026 1118244348 CMS
Boehringer Ingelheim International GmbH $12.76 07/11/2024 Food and Beverage Undisputed 01/23/2026 1118244298 CMS
Boehringer Ingelheim International GmbH $12.76 07/11/2024 Food and Beverage Undisputed 01/23/2026 1118244300 CMS
Boehringer Ingelheim International GmbH $32.72 07/11/2024 Food and Beverage Undisputed 01/23/2026 1118244302 CMS
Boehringer Ingelheim International GmbH $81.81 07/11/2024 Food and Beverage Undisputed 01/23/2026 1118244304 CMS
Boehringer Ingelheim International GmbH $434.14 07/11/2024 Travel and Lodging Undisputed 01/23/2026 1118244308 CMS
Boehringer Ingelheim International GmbH $3,250.00 07/19/2024 Consulting Fee Undisputed 01/23/2026 1118244334 CMS
Boehringer Ingelheim International GmbH $1,300.00 08/19/2024 Consulting Fee Undisputed 01/23/2026 1118244312 CMS
Boehringer Ingelheim International GmbH $7,087.71 08/19/2024 Travel and Lodging Undisputed 01/23/2026 1118244352 CMS
Boehringer Ingelheim International GmbH $3,900.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 1118244342 CMS
Boehringer Ingelheim International GmbH $267.21 10/18/2024 Travel and Lodging Undisputed 01/23/2026 1118244306 CMS
Boehringer Ingelheim International GmbH $8,100.00 10/18/2024 Consulting Fee Undisputed 01/23/2026 1118244354 CMS
Boehringer Ingelheim International GmbH $4,225.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1118244346 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3,750.00 01/18/2024 Consulting Fee Undisputed 01/23/2026 1118244338 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $6,337.50 02/26/2024 Consulting Fee Undisputed 01/23/2026 1118244350 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,950.00 03/20/2024 Consulting Fee Undisputed 01/23/2026 1118244316 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,275.00 04/19/2024 Consulting Fee Undisputed 01/23/2026 1118244322 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $4,225.00 05/08/2024 Consulting Fee Undisputed 01/23/2026 1118244344 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,600.00 06/18/2024 Consulting Fee Undisputed 01/23/2026 1118244328 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3,900.00 07/19/2024 Consulting Fee Undisputed 01/23/2026 1118244340 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,112.50 08/16/2024 Consulting Fee Undisputed 01/23/2026 1118244320 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,600.00 09/18/2024 Consulting Fee Undisputed 01/23/2026 1118244330 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,950.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 1118244318 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 11/15/2024 Consulting Fee Undisputed 01/23/2026 1118244310 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,275.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 1118244324 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $2,640.00 02/09/2024 Consulting Fee Undisputed 01/23/2026 1118840173 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $220.00 12/03/2024 Consulting Fee Undisputed 01/23/2026 1118840175 CMS
Travere Therapeutics, Inc. $759.59 01/23/2024 Consulting Fee Undisputed 01/23/2026 1149918785 CMS
Travere Therapeutics, Inc. $3,490.41 01/23/2024 Consulting Fee Undisputed 01/23/2026 1149918808 CMS
Travere Therapeutics, Inc. $2,250.00 02/13/2024 Consulting Fee Undisputed 01/23/2026 1149918800 CMS
Travere Therapeutics, Inc. $750.00 03/19/2024 Consulting Fee Undisputed 01/23/2026 1149918764 CMS
Travere Therapeutics, Inc. $4,000.00 03/19/2024 Consulting Fee Undisputed 01/23/2026 1149918812 CMS
Travere Therapeutics, Inc. $750.00 04/16/2024 Consulting Fee Undisputed 01/23/2026 1149918768 CMS
Travere Therapeutics, Inc. $750.00 04/16/2024 Consulting Fee Undisputed 01/23/2026 1149918772 CMS
Travere Therapeutics, Inc. $1,750.00 06/17/2024 Consulting Fee Undisputed 01/23/2026 1149918793 CMS
Travere Therapeutics, Inc. $750.00 07/16/2024 Consulting Fee Undisputed 01/23/2026 1149918776 CMS
Travere Therapeutics, Inc. $3,375.00 08/13/2024 Consulting Fee Undisputed 01/23/2026 1149918804 CMS
Travere Therapeutics, Inc. $2,000.00 09/17/2024 Consulting Fee Undisputed 01/23/2026 1149918796 CMS
Travere Therapeutics, Inc. $750.00 10/15/2024 Consulting Fee Undisputed 01/23/2026 1149918781 CMS
Travere Therapeutics, Inc. $1,000.00 12/17/2024 Consulting Fee Undisputed 01/23/2026 1149918789 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.